Journal of Biological Chemistry · 2006 · 69 citations · 37 references
Life SciencesBiologyMolecular BiologyMolecular VirologyStructural BiologyVirologyBinding KineticsLigand BindingProtein-ligand BindingProtein-ligand InteractionsViral StructureViral TropismAntiviral Structure-activity RelationshipsEntry Of Enveloped VirusesHelix-turn-helix ProteinsLigand Binding AffinityViral Entry InhibitorsViral Fusion ProteinsViral Membrane FusionVirus-host Membrane Interactions
Infection by human immunodeficiency virus type 1 (HIV-1) involves the fusion of viral and cellular membranes mediated by formation of the gp41 trimer-of-hairpins. A designed protein, 5-Helix, targets the C-terminal region of the gp41 ectodomain, disrupting trimer-of-hairpins formation and blocking viral entry. Here we show that the nanomolar inhibitory potency of 5-Helix (IC50 ∼6 nm) is 4 orders of magnitude larger than its subpicomolar binding affinity (KD ∼0.6 pm). This discrepancy results from the transient exposure of the 5-Helix binding site on gp41. As a consequence, inhibitory potency is determined by the association rate, not by binding affinity. For a series of 5-Helix variants with mutations in their gp41 binding sites, the IC50 and KD values poorly correlate. By contrast, an inverse relationship between IC50 values and association rate constants (kon) extends for over 2 orders of magnitude. The kinetic dependence to inhibition places temporal restrictions on an intermediate state of HIV-1 membrane fusion and suggests that access to the C-terminal region of the gp41 ectodomain is largely free from steric hindrance. Our results support the importance of association kinetics in the development of improved HIV-1 fusion inhibitors. Infection by human immunodeficiency virus type 1 (HIV-1) involves the fusion of viral and cellular membranes mediated by formation of the gp41 trimer-of-hairpins. A designed protein, 5-Helix, targets the C-terminal region of the gp41 ectodomain, disrupting trimer-of-hairpins formation and blocking viral entry. Here we show that the nanomolar inhibitory potency of 5-Helix (IC50 ∼6 nm) is 4 orders of magnitude larger than its subpicomolar binding affinity (KD ∼0.6 pm). This discrepancy results from the transient exposure of the 5-Helix binding site on gp41. As a consequence, inhibitory potency is determined by the association rate, not by binding affinity. For a series of 5-Helix variants with mutations in their gp41 binding sites, the IC50 and KD values poorly correlate. By contrast, an inverse relationship between IC50 values and association rate constants (kon) extends for over 2 orders of magnitude. The kinetic dependence to inhibition places temporal restrictions on an intermediate state of HIV-1 membrane fusion and suggests that access to the C-terminal region of the gp41 ectodomain is largely free from steric hindrance. Our results support the importance of association kinetics in the development of improved HIV-1 fusion inhibitors. HIV-1 2The abbreviations used are: HIV-1, human immunodeficiency virus type 1; Env, HIV-1 envelope glycoprotein; HR, 3,4-hydrophobic heptad repeat; R-C37, rhodamine-labeled C-peptide C37; TBS, Tris-buffered saline. cellular invasion proceeds through fusion of viral and cellular membranes, a process mediated by the viral surface glycoprotein Env in response to binding cellular receptors (1Eckert D.M. Kim P.S. Annu. Rev. Biochem. 2001; 70: 777-810Crossref PubMed Scopus (1151) Google Scholar, 2Pierson T.C. Doms R.W. Curr. Top. Microbiol. Immunol. 2003; 281: 1-27PubMed Google Scholar). Functional Env is composed of two noncovalently linked subunits, gp120 and gp41, arranged as a trimer of heterodimers on the virion surface. The interaction of gp120 with cellular CD4 and a chemokine receptor promotes structural rearrangements that ultimately lead gp41 to insert its N-terminal fusion peptide segment into the target cell membrane (Fig. 1A). Eventually, gp41 collapses into a stable, compact trimer-of-hairpins conformation essential for efficient membrane fusion (3Root M.J. Steger H.K. Curr. Pharm. Des. 2004; 10: 1805-1825Crossref PubMed Scopus (94) Google Scholar). The core of the gp41 trimer-of-hairpins is a bundle of six α-helices formed by two hydrophobic heptad repeat sequences (HR1 and HR2) within each of the three gp41 ectodomains (4Lu M. Blacklow S.C. Kim P.S. Nat. Struct. Biol. 1995; 2: 1075-1082Crossref PubMed Scopus (674) Google Scholar, 5Chan D.C. Fass D. Berger J.M. Kim P.S. Cell. 1997; 89: 263-273Abstract Full Text Full Text PDF PubMed Scopus (1848) Google Scholar, 6Weissenhorn W. Dessen A. Harrison S.C. Skehel J.J. Wiley D.C. Nature. 1997; 387: 426-430Crossref PubMed Scopus (1470) Google Scholar, 7Tan K. Liu J. Wang J. Shen S. Lu M. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 12303-12308Crossref PubMed Scopus (519) Google Scholar). The N-terminal HR1 segments form a central, trimeric coiled coil. The C-terminal HR2 segments pack in an antiparallel manner into hydrophobic grooves on the exterior of the HR1 coiled coil. The antiparallel packing of HR1 and HR2 segments ensures that the fusion peptide and transmembrane region of gp41 are brought into close proximity (Fig. 1A). Since the fusion peptide is inserted within the target cell membrane and the transmembrane region is embedded within the viral membrane, formation of the gp41 trimer-of-hairpins promotes the juxtaposition of the two membranes (6Weissenhorn W. Dessen A. Harrison S.C. Skehel J.J. Wiley D.C. Nature. 1997; 387: 426-430Crossref PubMed Scopus (1470) Google Scholar). The similarity of the gp41 trimer-of-hairpins to the fusion-active conformations of glycoproteins from distantly related enveloped viruses suggests that this structure plays a critical role in promoting viral membrane fusion (see Ref. 3Root M.J. Steger H.K. Curr. Pharm. Des. 2004; 10: 1805-1825Crossref PubMed Scopus (94) Google Scholar and references therein). Peptides derived from the HR2 region of the gp41 ectodomain can disrupt formation of the gp41 trimer-of-hairpins, thereby inhibiting HIV-1 entry (4Lu M. Blacklow S.C. Kim P.S. Nat. Struct. Biol. 1995; 2: 1075-1082Crossref PubMed Scopus (674) Google Scholar, 8Wild C.T. Shugars D.C. Greenwell T.K. McDanal C.B. Matthews T.J. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 9770-9774Crossref PubMed Scopus (888) Google Scholar, 9Jiang S. Lin K. Strick N. Neurath A.R. Nature. 1993; 365: 113Crossref PubMed Scopus (480) Google Scholar). Denoted as C-peptides, they work in a dominant negative fashion by binding the gp41 HR1 regions exposed in the extended, prehairpin intermediate conformation (4Lu M. Blacklow S.C. Kim P.S. Nat. Struct. Biol. 1995; 2: 1075-1082Crossref PubMed Scopus (674) Google Scholar, 10Chan D.C. Chutkowski C.T. Kim P.S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 15613-15617Crossref PubMed Scopus (485) Google Scholar, 11Rimsky L.T. Shugars D.C. Matthews T.J. J. Virol. 1998; 72: 986-993Crossref PubMed Google Scholar, 12Furuta R.A. Wild C.T. Weng Y. Weiss C.D. Nat. Struct. Biol. 1998; 5: 276-279Crossref PubMed Scopus (467) Google Scholar, 13Kilgore N.R. Salzwedel K. Reddick M. Allaway G.P. Wild C.T. J. Virol. 2003; 77: 7669-7672Crossref PubMed Scopus (68) Google Scholar). Once bound, they prevent association of the HR1 and HR2 segments, thus blocking viral membrane fusion. That C-peptides bind an intermediate state in the fusion process is supported by the following observations: 1) C-peptides can precipitate gp41 only after Env binds cellular receptors (12Furuta R.A. Wild C.T. Weng Y. Weiss C.D. Nat. Struct. Biol. 1998; 5: 276-279Crossref PubMed Scopus (467) Google Scholar, 13Kilgore N.R. Salzwedel K. Reddick M. Allaway G.P. Wild C.T. J. Virol. 2003; 77: 7669-7672Crossref PubMed Scopus (68) Google Scholar); 2) the extent of inhibition depends on C-peptide concentration present during membrane fusion and not on preincubation levels (12Furuta R.A. Wild C.T. Weng Y. Weiss C.D. Nat. Struct. Biol. 1998; 5: 276-279Crossref PubMed Scopus (467) Google Scholar); 3) conditions that alter the rate of gp41-mediated membrane fusion influence the inhibitory potency of C-peptides (14Reeves J.D. Gallo S.A. Ahmad N. Miamidian J.L. Harvey P.E. Sharron M. Pohlmann S. Sfakianos J.N. Derdeyn C.A. Blumenthal R. Hunter E. Doms R.W. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 16249-16254Crossref PubMed Scopus (379) Google Scholar, 15Melikyan G.B. Markosyan R.M. Hemmati H. Delmedico M.K. Lambert D.M. Cohen F.S. J. Cell Biol. 2000; 151: 413-423Crossref PubMed Scopus (486) Google Scholar, 16Abrahamyan L.G. Mkrtchyan S.R. Binley J. Lu M. Melikyan G.B. Cohen F.S. J. Virol. 2005; 79: 106-115Crossref PubMed Scopus (74) Google Scholar); and 4) at intermediate concentrations that block fusion pore formation, C-peptides can lock gp41 in a state that still permits lipid mixing (17Munoz-Barroso I. Durell S. Sakaguchi K. Appella E. Blumenthal R. J. Cell Biol. 1998; 140: 315-323Crossref PubMed Scopus (269) Google Scholar). Despite the transient exposure of their binding site, some C-peptides possess potent (low nanomolar) inhibitory activity in vitro. One C-peptide, T20 (enfuvirtide), also demonstrates antiviral activity in vivo and has been approved by the FDA for treatment of HIV-1 infected individuals (18Lalezari J.P. Henry K. O'Hearn M. Montaner J.S. Piliero P.J. Trottier B. Walmsley S. Cohen C. Kuritzkes D.R. Eron Jr., J.J. Chung J. DeMasi R. Donatacci L. Drobnes C. Delehanty J. Salgo M. N. Engl. J. Med. 2003; 348: 2175-2185Crossref PubMed Scopus (840) Google Scholar, 19Lazzarin A. Clotet B. Cooper D. Reynes J. Arasteh K. Nelson M. Katlama C. Stellbrink H.J. Delfraissy J.F. Lange J. Huson L. DeMasi R. Wat C. Delehanty J. Drobnes C. Salgo M. N. Engl. J. Med. 2003; 348: 2186-2195Crossref PubMed Scopus (616) Google Scholar). In a complementary manner, agents that specifically target the gp41 HR2 segment also block HIV-1 entry. N-peptides, derived from the gp41 HR1 region, can inhibit through this mechanism, but their tendency to aggregate in physiological solutions severely limits their potency (4Lu M. Blacklow S.C. Kim P.S. Nat. Struct. Biol. 1995; 2: 1075-1082Crossref PubMed Scopus (674) Google Scholar, 20Wild C. Oas T. McDanal C. Bolognesi D. Matthews T. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 10537-10541Crossref PubMed Scopus (483) Google Scholar, 21Eckert D.M. Kim P.S. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 11187-11192Crossref PubMed Scopus (251) Google Scholar, 22Louis J.M. Bewley C.A. Clore G.M. J. Biol. Chem. 2001; 276: 29485-29489Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar). However, engineered proteins that expose all or part of the HR1 coiled coil in soluble form display potent, broad-spectrum inhibitory activity (mid-picomolar to low nanomolar). In one design strategy, three HR1 and two HR2 segments that form the core of the gp41 trimer-of-hairpins been linked into a 5-Helix M.J. Kim P.S. 2001; PubMed Scopus Google Scholar). 5-Helix a HR2 and this a affinity C-peptide binding In a design strategy, of are linked to as a soluble coiled coil D.M. Kim P.S. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 11187-11192Crossref PubMed Scopus (251) Google Scholar, E. M. R. R. A. Proc. Natl. Acad. Sci. U. S. A. 2005; PubMed Scopus Google Scholar, J.M. I. L. Clore G.M. Bewley C.A. J. Biol. Chem. 2003; Full Text Full Text PDF PubMed Scopus Google or a bundle J.M. Bewley C.A. Clore G.M. J. Biol. Chem. 2001; 276: 29485-29489Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar). expose three C-peptide binding sites, and of interaction plays a role in their inhibitory is at during fusion the gp41 HR2 segment to engineered suggests that designed proteins bind the conformation of Env to receptor C-peptides, 5-Helix can precipitate Env from cellular and viral membranes in the of CD4 or M.J. Proc. Natl. Acad. Sci. U. S. A. 2003; PubMed Scopus Google Scholar, T. D.C. J. Biol. Chem. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). This interaction a 5-Helix to Env the for receptor M.J. Proc. Natl. Acad. Sci. U. S. A. 2003; PubMed Scopus Google Scholar). However, the extent of interaction is and 5-Helix binding to a form of the interaction is in the of receptors M.J. Proc. Natl. Acad. Sci. U. S. A. 2003; PubMed Scopus Google Scholar, T. D.C. J. Biol. Chem. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar, J.M. Bewley C.A. Clore G.M. Blumenthal R. 2005; PubMed Scopus Google that 5-Helix bind to an intermediate state of fusion. with this inhibition of the HR2 region is to gp41 mutations that disrupt trimer-of-hairpins formation and alter the kinetics of membrane fusion L.G. Mkrtchyan S.R. Binley J. Lu M. Melikyan G.B. Cohen F.S. J. Virol. 2005; 79: 106-115Crossref PubMed Scopus (74) Google Scholar, Lu M. J. Virol. 2002; PubMed Scopus Google Scholar). we an to the temporal of the gp41 HR2 segment during membrane fusion. a series of 5-Helix variants with mutations within their C-peptide binding sites, we the relationship between inhibitory binding and association that the potency of an of binding Env largely on its binding affinity. to this we that binding affinity is a of inhibitory an inverse relationship is between IC50 inhibitory and the association rate This dependence is for an that targets a transient state in the fusion Our results temporal and restrictions on the exposure of the C-terminal region of the gp41 and of 5-Helix of and or in into 5-Helix at and of the segments to the Env of the HR1 in the in a of the HR1 coiled coil M.J. Kim P.S. 2001; PubMed Scopus Google and hydrophobic with the HR2 For the and in all three segments For of into the segment only for the and variants (see for on and 5-Helix proteins in and conditions on in 4 by from to from by in determined to by The concentrations of all 5-Helix variants determined by at in H. PubMed Scopus Google Scholar). and for each determined by and are in inhibitory and binding of 5-Helix and its variants of the C-peptide binding site on 5-Helix by the into all three segments or only the segment for For each the and by of at and The inhibitory potency for each determined in the fusion Env and and target The KD and the by the C-peptide concentration in of and 5-Helix For the two variants with an the IC50 and values from the in as are the the of 5-Helix variants and the magnitude of in of the and and of C-peptide in the HR2 from or Env to the from C-peptide by of the trimer-of-hairpins (see Ref. M.J. Kim P.S. 2001; PubMed Scopus Google Scholar and for The peptide and to by The of by and its concentration determined by at in an of viral and fusion as D.C. Chutkowski C.T. Kim P.S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 15613-15617Crossref PubMed Scopus (485) Google with as in the KD and values determined for the interaction of rhodamine-labeled and 5-Helix in The binding by the free concentration of as through the cell of a a of by 5-Helix and in 1 at 4 binding on the in 1 1 at for 1 the into of For each the of the through the cell on a to a pack within the solutions over this a of free within the cell and as an in that this the free concentrations in for to and at in solutions of and 1 For 5-Helix variants into concentrations of and for determined to that been through the in and the in the and after to a binding 1) and from in and and and to the concentrations of and 5-Helix The KD values this within of the values determined a for binding variants (KD or a for binding variants not For association kinetics solutions of nm) and 5-Helix in a for a of through the The of binding by the to on the or 5-Helix the of a of 5-Helix concentration (see A and The from to a kinetics 3) The values and the as in is the and KD is the determined For type 5-Helix and the the values a association (see the type rate determined by with the as for a interaction not of 5-Helix and of three and two C-peptides by M.J. Kim P.S. 2001; PubMed Scopus Google Scholar). that the core of 5-Helix the structure of the gp41 trimer-of-hairpins one HR2 (Fig. and M. J. in The hydrophobic by this with C-peptides and 5-Helix to inhibit membrane fusion at low nanomolar concentrations (Fig. The IC50 values are of viral concentrations for or cell concentrations in fusion (see 5-Helix inhibitory potency an of the Env with target and is not by to the of Env on viral or cellular virus at 5-Helix concentrations to for not 5-Helix inhibitory activity (Fig. 5-Helix with Env to receptor is for the to with its binding site during 5-Helix can with Env, inhibitory potency with binding affinity. inhibition through an intermediate state with a to potency by association between we a series of 5-Helix variants with mutations in one or of that form hydrophobic with the HR2 segment (Fig. all are to the protein, inhibitory activity in the structure and we the or in to or The IC50 values of the 5-Helix variants from to in a fusion (Fig. In variants with to than variants with only with the hydrophobic of the interaction between 5-Helix and the HR2 with one IC50 values from that of type variants with three are still with IC50 values within a of six of the type 5-Helix of to binding determined a of 5-Helix and a rhodamine-labeled C-peptide through a cell a of A of the free specifically in the in an in to the free concentration of in In the in a of a that with the of through the of 5-Helix to this the by that only of in of 5-Helix at we determined the KD to for the type (Fig. The binding of the variants than orders of magnitude. inhibiting variants to low binding the IC50 and KD values show in For the KD values for the variants from to but this is not in their IC50 values and binding is than 4 orders of magnitude in the their IC50 values are than than the type However, an that binds with affinity as the variants with potency than type The of between IC50 and KD values is with an of inhibition (Fig. of on 5-Helix on we that the inhibitory target of 5-Helix is exposed during a intermediate The that this inhibition is by and the and the conformations of gp41, The rate constants and the kinetics of 5-Helix binding to the The constants and to the of and of intermediate The from to a state is to prevent the from into in the of The results of this not the of this this we can the discrepancy between IC50 and KD for type inhibition by 5-Helix that its binding rate on the of or than 5-Helix at low concentrations is of binding than of Env, the to association at the Since the intermediate state of gp41 for (17Munoz-Barroso I. Durell S. Sakaguchi K. Appella E. Blumenthal R. J. Cell Biol. 1998; 140: 315-323Crossref PubMed Scopus (269) Google Scholar, J.M. Bewley C.A. Clore G.M. Blumenthal R. 2005; PubMed Scopus Google 5-Helix bind and fusion proceeds the concentration is into the nanomolar 5-Helix binds Env with and inhibition is The kinetic to inhibition that 5-Helix variants concentrations in to we IC50 values to with this we the association of 5-Helix and by the (Fig. The association rate for type 5-Helix is close to the association rate for (Fig. The potent variants that only association rate constants within a of of the type By contrast, the association rate constants of the potent and are to than the type In an inverse relationship between the IC50 and extends for over 2 orders of magnitude (Fig. with the of the inhibition the of the for IC50 derived from the inhibition 1 is as (see for For the of the IC50 and are (Fig. that the to the state with two variants from this inverse and they possess the two rate is poorly determined the and are (see However, the is determined and to the that the intermediate state of gp41 has an of only a to the between of association rate constants and inhibitory the of the IC50 relationship (Fig. the of binding that values by a as is from to (see The of this to this the of the IC50 a for the intermediate A dependence between IC50 and is for 5-Helix inhibition of HIV-1 with or Env (Fig. in the of in values that on target cell For a relationship is for target that levels of that Env through the intermediate state to of and virus are on the values are the or in in the 5-Helix of virus is a of kinetic and not to binding affinity. In this we essential of 5-Helix inhibition of HIV-1 membrane fusion. the of inhibition depends on 5-Helix concentration present during membrane fusion and not on preincubation 5-Helix binds with subpicomolar affinity but with nanomolar a is between inhibitory potency and interaction affinity for a series of 5-Helix variants with C-peptide the IC50 values for variants are to their association rate The between inhibitory binding and association kinetics lead to that 5-Helix targets a intermediate state of gp41 during the membrane fusion can inhibitory the transient exposure of the 5-Helix inhibitory with the interaction of 5-Helix with Env M.J. Proc. Natl. Acad. Sci. U. S. A. 2003; PubMed Scopus Google Scholar, T. D.C. J. Biol. Chem. 2003; Full Text Full Text PDF PubMed Scopus Google suggests that Env in on the surface of viruses and with only a for membrane fusion C. C. D.R. S. J.P. J. Virol. 2003; 77: PubMed Scopus Google Scholar, M. E. M. S. Wang M. D.R. J. Virol. 2003; 77: PubMed Scopus Google Scholar). This has been to for the of to block the antiviral activity of a to with the for binding to The of of Env in viral and cellular membranes as to development of a potent response L. H. M. L. D.R. Binley J.M. J. Virol. PubMed Scopus Google Scholar). that binding to one or of conformations for the interaction of 5-Helix with In the of the intermediate state of gp41 is related to the of the dependence between IC50 and The in for and Env in in their structure that alter to or of the trimer-of-hairpins However, on the target as also an on levels been with of Env fusion and potency of C-peptide (14Reeves J.D. Gallo S.A. Ahmad N. Miamidian J.L. Harvey P.E. Sharron M. Pohlmann S. Sfakianos J.N. Derdeyn C.A. Blumenthal R. Hunter E. Doms R.W. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 16249-16254Crossref PubMed Scopus (379) Google Scholar). A is for inhibition by are binding to gp120 is to the exposure of the gp41 HR2 In to the dependence of IC50 on the exposure of the gp41 HR2 that 5-Helix to the inhibitory target a association rate for 5-Helix binding to gp41. The IC50 in this to and the of the IC50 on this (see for The of that is and that 5-Helix steric in binding gp41. the IC50 to determined by the that the association of 5-Helix and through access to the gp41 HR2 region is for intermediate of fusion in to the of gp41 and the two membranes, a chemokine and surface proteins on the virus and target cell Kim S. J. Biol. Chem. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). However, steric for 5-Helix inhibition is with the of two and that bind at the of the gp41 HR2 region T. M. A. A. H. J. Virol. 1993; PubMed Google Scholar, Wang M. C. Binley J.M. J.P. H. D.R. J. Virol. 2001; PubMed Scopus Google Scholar, M. A. H. R. J. Virol. 2004; PubMed Scopus Google Scholar). a of intermediate state inhibition 1 and that the HR2 region is to 5-Helix for only a during the fusion The of this depends on the interaction between 5-Helix and in 5-Helix binding to gp41 in the viral For steric is to a role in the rate of 5-Helix association with gp41. that influence the kinetic of gp41 binding 1) of the on the concentration of 5-Helix and 2) of the HR2 segment not in the peptide at or the rate of 5-Helix association with gp41, to an or of the of the intermediate The of the with the suggests that into they influence all 5-Helix variants to the The from an Env to trimer-of-hairpins conformation has been to as as (17Munoz-Barroso I. Durell S. Sakaguchi K. Appella E. Blumenthal R. J. Cell Biol. 1998; 140: 315-323Crossref PubMed Scopus (269) Google Scholar, J.M. Bewley C.A. Clore G.M. Blumenthal R. 2005; PubMed Scopus Google Scholar). from fusion by following the of HR1 coiled coil C-peptide inhibitory and fusion pore The by specifically the of the intermediate state to 5-Helix can This state for only a of the between Env and trimer-of-hairpins as a in this to a process that can at conditions for membrane G.B. Markosyan R.M. Hemmati H. Delmedico M.K. Lambert D.M. Cohen F.S. J. Cell Biol. 2000; 151: 413-423Crossref PubMed Scopus (486) Google Scholar, 16Abrahamyan L.G. Mkrtchyan S.R. Binley J. Lu M. Melikyan G.B. Cohen F.S. J. Virol. 2005; 79: 106-115Crossref PubMed Scopus (74) Google Scholar, R.M. Cohen F.S. Melikyan G.B. Biol. Cell. 2003; PubMed Scopus Google Scholar). suggests that the HR1 and HR2 regions are not exposed as intermediate trimer-of-hairpins formation L.G. Mkrtchyan S.R. Binley J. Lu M. Melikyan G.B. Cohen F.S. J. Virol. 2005; 79: 106-115Crossref PubMed Scopus (74) Google Scholar). in HR1 and HR2 exposure has been for membrane fusion R.A. J. 2001; PubMed Scopus Google Scholar). The binding affinity of 5-Helix and the kinetic of its inhibitory that Env in a state that the HR2 region to this are to the conditions that an the are and to on the temporal and exposure of the gp41 HR1 segment during the C-peptide intermediate Our results support the of association kinetics as an in the development of improved fusion transient gp41 potency through that concentration the viral membrane, by agents or with surface binding concentration for the antiviral activity of the E. M. R. R. A. Proc. Natl. Acad. Sci. U. S. A. 2005; PubMed Scopus Google Scholar). This linked trimeric peptide has three binding that each with a of the gp41 HR2 region Kim P.S. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: PubMed Scopus Google Scholar). one or two of its three binding sites, this with the virion surface through Env glycoproteins or gp41 The binding on thus to with an HR2 region of an Env following its by cellular In this manner, the kinetic by 5-Helix and inhibit with S. R. M. M. J. and for their during the of M. and R. Doms for and J. C. J. and of the for and critical with
37
Identification of a major co-receptor for primary isolates of HIV-1
Hongkui Deng, Rong Liu, Wilfried Ellmeier et al. · Nature · 1996 · 3.7K citations
Core Structure of gp41 from the HIV Envelope Glycoprotein
David C. Chan, Deborah Fass, James M. Berger et al. · Cell · 1997 · 1.9K citations · Full text
Atomic structure of the ectodomain from HIV-1 gp41
Winfríed Weissenhorn, Andréa Dessen, Stephen C. Harrison et al. · Nature · 1997 · 1.6K citations
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
Thomas Muster, Franz Steindl, Martin Purtscher et al. · Journal of Virology · 1993 · 988 citations · Full text